The method of removing the lens of the eye from the vitreous cavity

 

(57) Abstract:

The invention relates to medicine, namely to ophthalmology, and can be used to remove the lens from the vitreous cavity. The eye lens is removed through an incision in the flat part of the ciliary body by phacoemulsification. Through the same incision implanted artificial lens. The method allows atraumatic to delete their own lens and implant an artificial lens. 6 Il.

The invention relates to medicine, namely to ophthalmology, and can be used to remove native lens of the eye of the patient, fully vivanativa in the vitreous body.

A known method of removing the lens of the eye from the vitreous cavity, including a cut in the flat part of the ciliary body, Subtotal vitrectomy, filling the vitreous cavity performancesin connection (PFOS), the rise of the lens to the area of the pupil, the removal of PFOS (RU patent 2064785, a 61 F 9/00).

However, removal of the lens from the eye and implantation of artificial lens requires a large corneal or MS who-corneal incision, which increases the invasiveness of the surgery and omelich">

The objective of the invention is to develop a noninvasive method of removing their own lens of the eye of the patient, fully vivanativa in the vitreous body, and implantation of an artificial lens.

The technical result that is achievable with the use of the invention is the reduction of operational and post-operative complications due to the reduction of incision and reduction of traumatic retinal, corneal endothelium, iris and anterior chamber angle.

The method is as follows.

Under local anesthesia insert vekorasshiriteli, the upper straight muscle take on the seam-taped. The conjunctiva usepreview from the limbus in the upper and outer quadrant of the eyeball. 4.0 mm from the limbus make three micro-incision of the sclera (sclerotome) 1.0 mm, which are located in ninananajna, verhnovodjane and upper outer quadrants. In sclerotomy in ninananajna quadrant hem cannula 1 for intraocular irrigation - Fig. 1. The remaining two sclerotomies serve for the introduction of the light guide 2 and vitrectomy 3. Perform a Subtotal removal of the vitreous body 5, while carefully release the lens 6 from the vitreal fibers. In the value of surface tension forces is at the top of the bubble PFOS - Fig. 2. More supply PFOS lens 6 is set for the iris - Fig. 3. The light guide and vitreum removed. In sclerotomies holes injected handpiece delivery 8 and the tool 9 for manipulation of the nucleus of the crystalline lens. Perform transilien phacoemulsification - Fig. 3. After that sclerotomy 10 in verhnovodjane quarante extend up to 3 mm and through it enter elastic artificial lens 11 - Fig. 4. The last lock seam 12 in the ciliary sulcus - Fig. 3. PFOS aspiritual through the cannula 13 - Fig. 6. Paracentesis in the sclera and the conjunctiva is sutured interrupted sutures (silk 8/0). The surgery is completed by the introduction of a solution of the antibiotic and corticosteroid subconjunctival.

Example: Patient W., 62 years old, was admitted with a diagnosis of complete traumatic dislocation own lens into the vitreous body on the right eye, traumatic cataract, myopia of a high degree. Visual acuity of 0.01 sph+11.0= 0.8, IOP of 21 mm RT.article, the field of view - normal length eyes 24.00 mm, ophthalmometry 0 deg.- 41.00 D, 90 deg.- 41.75 D. When biomicroscopy: calm eyes, the cornea is spherical, transparent, front camera 4.0 mm, uniform moisture transparent, the pupil in the centre, reaction to light alive, iridotomies. In the vitreous body expressed dblast no focal pathology. Private diffuse lens is cloudy and is located in the region of the equator in the lower half of the vitreal cavity in the retina, is not fixed, when the movements of the eye changes its position. In the preoperative period patient was performed transpupillary peripheral argon laser coagulation of the retina. Through 1 month after the formation of the laser coagulates began to surgical treatment.

The progress of the operation. After local anesthesia and akinesia of the eyeball 4% lidocaine solution, put vekorasshiriteli and recorded on the seam-taped top straight muscle. The conjunctiva was useprofile from the limbus in the upper and outer quadrant of the eyeball. 4 mm from the limbus performed 3 micro-incision of the sclera length is 1.0 mm, which was placed on 2, 11 and 7 hours. In sclerotomy in ninananajna quadrant for 7 hours sewed irrigation cannula. Through sclerotomy 2 and 11 hours entered the light guide and vitreum. Performed Subtotal vitrectomy using beveled silicone fundus lens. Carefully freed the lens from the vitreal fibers. In the vitreous cavity through a cannula introduced PFOS. As you fill the vitreous cavity of PFOS, is out with a twisted lens is located on the top g is to the anterior segment of the eyeball and was installed behind the iris. The light guide and vitreum learned. In sclerotomies holes introduced the tip of the delivery STORZ PREMIER and tools for manipulation of the nucleus of the crystalline lens. Performed transilien phacoemulsification. The remains of lenticular masses from the boundary surface of PFOS was removed by videocomm. Scleral incision was extended to 3 mm, and through him made implantation elastic artificial lens. Last fixed by sutures in the ciliary sulcus.

Next introduced the fiber and thin-walled cannula aspirated and PFOS. Paracentesis in the sclera and the conjunctiva was tighten up her interrupted sutures (silk 8/0). The operation ended with the introduction of a solution of the antibiotic (kanamycin) and a corticosteroid (dexamethasone) subconjunctival.

Visual acuity at discharge after 1 week after surgery was equal to 0.7. The intraocular pressure of 15 mm RT.art., field of view - no change, loss of corneal endothelium was just 7.6%. Visual function were stable during the whole observation period (1 year). The obtained results allow to conclude about the efficacy and safety of the proposed treatment method.

We used this technique in 9 patients (9 eyes). In neither case did not identify specific Oliynyk complications and, thus, to accelerate the visual and social rehabilitation of patients.

The method of removing the lens of the eye from the vitreous cavity, including a cut in the flat part of the ciliary body, Subtotal vitrectomy, filling the vitreous cavity performancesin connection (PFOS), the rise of the lens to the area of the pupil, the removal of PFOS, characterized in that the lens of the eye is removed by phacoemulsification through the same incision in the flat part of the ciliary body, and then through the same incision implanted IOL.

 

Same patents:

The invention relates to medicine, in particular to ophthalmology
The invention relates to medicine, ophthalmology

The invention relates to medicine, namely to ophthalmology, and can be used for the surgical treatment of glaucoma
The invention relates to medicine, namely to ophthalmology, intended for the treatment of glaucoma
The invention relates to medicine, namely to ophthalmology, and can be used in the surgical treatment of retinal detachment
The invention relates to medicine, namely to ophthalmology, and can be used in the surgical treatment of retinal detachment
The invention relates to ophthalmology and is intended for the formation of the musculoskeletal stump in case of evisceration
The invention relates to ophthalmic surgery and is designed for cataract extraction by phacoemulsification
The invention relates to medicine, namely to ophthalmology

FIELD: medicine.

SUBSTANCE: method involves introducing 0.1-0.3 ml of photosensitizing gel preliminarily activated with laser radiation, after having removed neovascular membrane. The photosensitizing gel is based on a viscoelastic of hyaluronic acid containing khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-2% by mass. The photosensitizing gel is in vitro activated with laser radiation having wavelength of 661-666 nm during 3-10 min with total radiation dose being equal to 100-600 J/cm2. The gel is introduced immediately after being activated. To compress the retina, vitreous cavity is filled with perfluororganic compound or air to be further substituted with silicon oil. The operation is ended with placing sutures on sclerotomy and conjunctiva areas. Compounds like chealon, viscoate or hyatulon are used as viscoelastic based on hyaluronic acid. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity.

EFFECT: excluded recurrences of surgically removed neovascular membrane and development of proliferative retinopathy and retina detachment; retained vision function.

3 cl, 5 dwg

FIELD: medicine.

SUBSTANCE: method involves introducing 0.1-0.3 ml of photosensitizing gel preliminarily activated with laser radiation, after having removed neovascular membrane. The photosensitizing gel is based on a viscoelastic of hyaluronic acid containing khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-2% by mass. The photosensitizing gel is in vitro activated with laser radiation having wavelength of 661-666 nm during 3-10 min with total radiation dose being equal to 100-600 J/cm2. The gel is introduced immediately after being activated. To compress the retina, vitreous cavity is filled with perfluororganic compound or air to be further substituted with silicon oil. The operation is ended with placing sutures on sclerotomy and conjunctiva areas. Compounds like chealon, viscoate or hyatulon are used as viscoelastic based on hyaluronic acid. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity.

EFFECT: excluded recurrences of surgically removed neovascular membrane and development of proliferative retinopathy and retina detachment; retained vision function.

3 cl, 5 dwg

FIELD: medicine.

SUBSTANCE: method involves making incision in conjunctiva. Direct muscle is exposed and separated. Forceps is applied to the separated muscle 4-7 cm far from the place of its attachment to sclera. The muscle is notched to 1/2 of its width 1-2 mm far from the forceps on the proximal side. The muscle is bluntly exfoliated. Muscle flap is turned to after cutting it from sclera. The flap end is sutured to sclera 1-5 mm distal from the previous attachment place. Eyeball is displaced in conjunctival sack to opposite side with respect to the feeble muscle. Interrupted sutures are placed on conjunctiva incision.

EFFECT: enhanced effectiveness in correcting large squint angles.

4 dwg

FIELD: medicine.

SUBSTANCE: method involves cutting off external wall of Schlemm's canal on the whole width extent of internal scleral flap bed after making non-penetrating deep sclerectomy operation. At least three drains are entirely introduced into Schlemm's canal lumen and arranged all over the whole circumference of the Schlemm's canal. Hydrated hydrogel is used as draining polymer material. The hydrogel contains 0.5-5.0% aminocaproic acid solution, etamzylate solution and diprospan solution.

EFFECT: increased and retained hypotensive action; increased distance between internal and external wall of Schlemm's canal; reduced risk of traumatic complications in implanting drains; avoided inflammatory response of eye structures.

1 dwg

FIELD: medicine; medical engineering.

SUBSTANCE: method involves introducing device for fixing retina rupture edges into vitreous cavity after having done subtotal vitrectomy. The device has a pair of microsurgical needles connected to each other with surgical thread. Required number of needle pairs is introduced in succession to have required number of straight segments for fixing rupture edge. Needle ends are brought out in pairs together with thread to external sclera surface and cut, and the thread ends are fixed near the sclera surface.

EFFECT: reduced risk of traumatic complications; reliability of retina rupture edges fixation.

3 cl

FIELD: medicine.

SUBSTANCE: method involves making incision in conjunctiva and Tenon's capsule of 3-4 mm in size in choroid hemangioma projection to sclera 3-4 mm far from limb. Tunnel is built between sclera and Tenon's capsule to extrasclerally introduce flexible polymer magnetolaser implant through the tunnel to the place, the choroid hemangioma is localized, after performing transscleral diaphanoscopic adjustment of choroid hemangioma localization and size, under visual control using guidance beam. The implant has permanent ring-shaped magnet in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 2-3 mTesla units intensity. It is arranged with its north pole turned towards the choroid hemangioma so that extrascleral implant laser radiator disposition. The other end of the implant is sutured to sclera 5-6 mm far from the limb with two interrupted sutures through prefabricated openings. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. 0.1-1% khlorin solution is injected in intravenous bolus dose of 0.8-1.1 mg/kg as photosensitizer and visual control of choroid hemangioma cells fluorescence and fluorescent diagnosis methods are applied. After saturating choroid hemangioma with the photosensitizer to maximum level, transscleral choroid hemangioma laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm with total radiation dose being equal to 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the intraocular neoplasm, repeated laser irradiation of the choroid hemangioma is carried out with radiation dose of 30-60 J/cm2.

EFFECT: enhanced effectiveness of treatment.

4 cl

FIELD: medicine.

SUBSTANCE: method involves making incision in conjunctiva and Tenon's capsule of 3-4 mm in size in choroid hemangioma projection to sclera 3-4 mm far from limb. Tunnel is built between sclera and Tenon's capsule to extrasclerally introduce flexible polymer magnetolaser implant through the tunnel to the place, the choroid hemangioma is localized, after performing transscleral diaphanoscopic adjustment of choroid hemangioma localization and size, under visual control using guidance beam. The implant has permanent ring-shaped magnet in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 2-3 mTesla units intensity. It is arranged with its north pole turned towards the choroid hemangioma so that extrascleral implant laser radiator disposition. The other end of the implant is sutured to sclera 5-6 mm far from the limb with two interrupted sutures through prefabricated openings. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. 0.1-1% khlorin solution is injected in intravenous bolus dose of 0.8-1.1 mg/kg as photosensitizer and visual control of choroid hemangioma cells fluorescence and fluorescent diagnosis methods are applied. After saturating choroid hemangioma with the photosensitizer to maximum level, transscleral choroid hemangioma laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm with total radiation dose being equal to 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the intraocular neoplasm, repeated laser irradiation of the choroid hemangioma is carried out with radiation dose of 30-60 J/cm2.

EFFECT: enhanced effectiveness of treatment.

4 cl

FIELD: medicine.

SUBSTANCE: method involves creating tunnel between sclera and Tenon's capsule in intraocular neoplasm projection. Intraocular neoplasm localization and size is adjusted by applying transscleral diaphanoscopic examination method. 0.1-0.3 ml of photosensitizing gel based on viscoelastic of hyaluronic acid, selected from group containing chealon, viscoate or hyatulon, is transsclerally introduced into intraocular neoplasm structure using special purpose needle in dosed manner. The photosensitizing gel contains khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-1% by mass. Flexible polymer magnetolaser implant is extrasclerally introduced into the built tunnel in intraocular neoplasm projection zone under visual control using guidance beam. The implant has permanent ring-shaped magnet axially magnetized and producing permanent magnetic field of 3-4 mTesla units intensity, in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The implant is arranged with its north pole turned towards the intraocular neoplasm so that implant laser radiator lens is extrasclerally arranged in intraocular neoplasm projection zone. The implant light guide is sutured to sclera 5-6 mm far from the limb with single interrupted suture. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transscleral intraocular neoplasm laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm. The treatment course being over, the flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, neodymium-iron-boron or samarium-iron-nitrogen. 0.1-1% khlorin solution as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is additionally intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg and repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2 15-20 min later during 30-90 s.

EFFECT: complete destruction of neoplasm; excluded its further growth.

4 cl

FIELD: medicine.

SUBSTANCE: method involves creating tunnel between sclera and Tenon's capsule in intraocular neoplasm projection. Intraocular neoplasm localization and size is adjusted by applying transscleral diaphanoscopic examination method. 0.1-0.3 ml of photosensitizing gel based on viscoelastic of hyaluronic acid, selected from group containing chealon, viscoate or hyatulon, is transsclerally introduced into intraocular neoplasm structure using special purpose needle in dosed manner. The photosensitizing gel contains khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-1% by mass. Flexible polymer magnetolaser implant is extrasclerally introduced into the built tunnel in intraocular neoplasm projection zone under visual control using guidance beam. The implant has permanent ring-shaped magnet axially magnetized and producing permanent magnetic field of 3-4 mTesla units intensity, in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The implant is arranged with its north pole turned towards the intraocular neoplasm so that implant laser radiator lens is extrasclerally arranged in intraocular neoplasm projection zone. The implant light guide is sutured to sclera 5-6 mm far from the limb with single interrupted suture. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transscleral intraocular neoplasm laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm. The treatment course being over, the flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, neodymium-iron-boron or samarium-iron-nitrogen. 0.1-1% khlorin solution as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is additionally intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg and repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2 15-20 min later during 30-90 s.

EFFECT: complete destruction of neoplasm; excluded its further growth.

4 cl

FIELD: medicine.

SUBSTANCE: method involves applying transscleral diaphanoscopic examination method for adjusting intraocular neoplasm localization and size. Rectangular scleral pocket is built 2/3 times as large as sclera thickness which base is turned from the limb. Several electrodes manufactured from a metal of platinum group are introduced into intraocular neoplasm structure via the built scleral pocket. Next to it, intraocular neoplasm electrochemical destruction is carried out in changing electrodes polarity with current intensity of 100 mA during 1-10 min, and the electrodes are removed. Superficial scleral flap is returned to its place and fixed with interrupted sutures. 0.1-2% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transpupillary laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2. the operation is ended with placing sutures on conjunctiva. Platinum, iridium or rhodium are used as the metals of platinum group. The number of electrodes is equal to 4-8. 0.1-1% khlorin solution, selected from group containing photolon, radachlorine or photoditazine, is additionally repeatedly intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2.

EFFECT: complete destruction of neoplasm; excluded tumor recurrence; reduced risk of tumor cells dissemination.

3 cl, 3 dwg

Up!